-
1
المؤلفون: Reinhard Dummer, Georgina V. Long, Caroline Robert, Hussein A. Tawbi, Keith T. Flaherty, Paolo A. Ascierto, Paul D. Nathan, Piotr Rutkowski, Oleg Leonov, Caroline Dutriaux, Mario Mandalà, Paul Lorigan, Pier Francesco Ferrucci, Jean Jacques Grob, Nicolas Meyer, Helen Gogas, Daniil Stroyakovskiy, Ana Arance, Jan C. Brase, Steven Green, Tomas Haas, Aisha Masood, Eduard Gasal, Antoni Ribas, Dirk Schadendorf
المساهمون: University of Zurich
المصدر: Journal of clinical oncology : official journal of the American Society of Clinical Oncology, vol 40, iss 13
Dummer, R, Long, G V, Robert, C, Tawbi, H A, Flaherty, K T, Ascierto, P A, Nathan, P D, Rutkowski, P, Leonov, O, Dutriaux, C, Mandalà, M, Lorigan, P, Ferrucci, P F, Grob, J J, Meyer, N, Gogas, H, Stroyakovskiy, D, Arance, A, Brase, J C, Green, S, Haas, T, Masood, A, Gasal, E, Ribas, A & Schadendorf, D 2022, ' Randomized Phase III Trial Evaluating Spartalizumab Plus Dabrafenib and Trametinib for BRAF V600-Mutant Unresectable or Metastatic Melanoma ', Journal of clinical oncology : official journal of the American Society of Clinical Oncology . https://doi.org/10.1200/JCO.21.01601Testمصطلحات موضوعية: Proto-Oncogene Proteins B-raf, Adult, Cancer Research, Skin Neoplasms, Adolescent, Pyridones, Clinical Trials and Supportive Activities, Clinical Sciences, Oncology and Carcinogenesis, Medizin, 610 Medicine & health, Pyrimidinones, Antibodies, Death Domain, Clinical Research, Neoplasms, Oximes, Antineoplastic Combined Chemotherapy Protocols, Receptors, Monoclonal, Genetics, Humans, Oncology & Carcinogenesis, Melanoma, Humanized, Cancer, Manchester Cancer Research Centre, ResearchInstitutes_Networks_Beacons/mcrc, Human Genome, Imidazoles, Evaluation of treatments and therapeutic interventions, 10177 Dermatology Clinic, Second Primary, Oncology, 6.1 Pharmaceuticals, Mutation
وصف الملف: 928_Dummer_R._et_al._Randomized_Phase_III_Trial_Evaluationg_Spartalizumab_plus_Dabrafenib_and_Trametinib_for_BRAF_V600_mutant_JCO_2022.pdf - application/pdf; application/pdf
الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::512e67c5f66bacf61087d7e838e0dc59Test
https://www.zora.uzh.ch/id/eprint/213526Test/ -
2
المؤلفون: Mario Mandalà, Juliette Murris, Paola Queirolo, Ana Arance, Caroline Dutriaux, Helen Gogas, Gabriella Liszkay, Ralf Gutzmer, Claus Garbe, Keith T. Flaherty, Abir Tadmouri Sellier, Naoya Yamazaki, Jeanne Suissa, Ivana Krajsová, Vanna Chiarion Sileni, Caroline Robert, Reinhard Dummer, Groot Jan de Willem, Paolo A. Ascierto, Ashwin Gollerkeri, Carmen Loquai, Dirk Schadendorf
المساهمون: University of Zurich
مصطلحات موضوعية: Male, 0301 basic medicine, Cancer Research, Skin Neoplasms, Health-related quality of life, Medizin, Hospitalisation rate, chemistry.chemical_compound, 0302 clinical medicine, Quality of life, Antineoplastic Combined Chemotherapy Protocols, Vemurafenib, Melanoma, Aged, 80 and over, Sulfonamides, 10177 Dermatology Clinic, Binimetinib, Middle Aged, Progression-Free Survival, humanities, Oncology, Tolerability, 030220 oncology & carcinogenesis, Female, Open label, medicine.drug, Adult, Proto-Oncogene Proteins B-raf, medicine.medical_specialty, 610 Medicine & health, BRAF(V600E−K) mutant Melanoma, Young Adult, 03 medical and health sciences, BRAF/MEK inhibitors Combination, Internal medicine, medicine, Humans, In patient, Encorafenib plus binimetinib, Aged, business.industry, Repeated measures design, medicine.disease, 030104 developmental biology, chemistry, Mutation, Quality of Life, Benzimidazoles, Carbamates, business
وصف الملف: 898_Gogas_H._et_al._Quality_of_life_in_patients_with_BRAF_mutant_melanoma_receiving_the_combination_encorafenib_plus_binimetinib_EJC_2021.pdf - application/pdf
الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::00b598bc6b0d5210f8adf8a69fd7b47bTest
https://www.zora.uzh.ch/id/eprint/203982Test/ -
3
المؤلفون: Sandrine Mansard, Philippe Saiag, Hervé Maillard, Amine Denden, Caroline Robert, Laurent Mortier, S. Dalac-Rat, Charlée Nardin, Olivier Dereure, Thierry Lesimple, Laurent Machet, Eve-Marie Neidhardt, Florent Grange, Alexandra Szenik, Caroline Dutriaux, Christophe Bedane, Céleste Lebbé, Jean-Jacques Grob
المساهمون: HAL UVSQ, Équipe, Biomarqueurs et essais cliniques en Cancérologie et Onco-Hématologie (BECCOH), Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Université Paris-Saclay, Hôpital Ambroise Paré [AP-HP], Service de dermatologie, Département de médecine oncologique [Gustave Roussy], Institut Gustave Roussy (IGR)-Institut Gustave Roussy (IGR), Service de dermatologie, vénéreologie et cancérologie cutanée [Hôpital de la Timone - APHM], Aix Marseille Université (AMU)-Assistance Publique - Hôpitaux de Marseille (APHM)- Hôpital de la Timone [CHU - APHM] (TIMONE), Centre de Recherche en Cancérologie de Marseille (CRCM), Aix Marseille Université (AMU)-Institut Paoli-Calmettes, Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), CHU Lille, Université de Lille, CHU Montpellier, Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Immunologie humaine, physiopathologie & immunothérapie (HIPI (UMR_S_976 / U976)), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Cité (UPCité), Service de Dermatologie [AP-HP Hôpital Saint-Louis], Hopital Saint-Louis [AP-HP] (AP-HP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), CHU Estaing [Clermont-Ferrand], CHU Clermont-Ferrand, Centre Hospitalier Universitaire de Reims (CHU Reims), Centre Léon Bérard [Lyon], Centre Eugène Marquis (CRLCC), Centre Hospitalier Régional Universitaire de Tours (CHRU Tours), Université Francois Rabelais [Tours], Service de Dermatologie [CHU Limoges], CHU Limoges, Service de dermatologie [CH Le Mans], Centre Hospitalier Le Mans (CH Le Mans), Service de Dermatologie (CHU de Dijon), Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand (CHU Dijon), Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon), Novartis Pharma S.A.S., CHU Bordeaux [Bordeaux], Amgen, Bristol-Myers Squibb, BMS, Pfizer, Merck, Novartis, Roche, Sanofi, Meso Scale Diagnostics, MSD, Novartis Pharma, Les Laboratories Pierre Fabre, This work was supported by Novartis Pharma S.A.S. , France., Philippe Saiag has received personal fees from Amgen, Bristol-Myers Squibb, MSD, Merck-Serono, Pfizer, Roche-Genentech, Pierre Fabre, Sanofi and Novartis, he has received non-financial support from Bristol-Myers Squibb, MSD, Roche-Genentech and Novartis, and has received a funding grant from Roche-Genentech., Céléste Lebbe has received honoraria from BMS, MSD, Roche, Novartis, Amgen, Merck, Pierre Fabre, Pfizer and Incyte, has acted as a consultant or has served as a member of an advisory board for BMS, and has received travel grant support from BMS and MSD., Jean-Jacques Grob has received honoraria from BMS, MSD, Merck, Pfizer, Incyte, Novartis, Roche, Amgen and Pierre Fabre, has received travel grant support from BMS, MSD and Roche, and has acted as a consultant and advisor for BMS, MSD, Roche, Novartis, Amgen, Merck, Pierre Fabre, Pfizer and Incyte., Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Paris (UP)
المصدر: European Journal of Cancer
European Journal of Cancer, 2021, 154, pp.57-65. ⟨10.1016/j.ejca.2021.05.031⟩
European Journal of Cancer, Elsevier, 2021, 154, pp.57-65. ⟨10.1016/j.ejca.2021.05.031⟩مصطلحات موضوعية: Adult, Male, Proto-Oncogene Proteins B-raf, Oncology, Cancer Research, medicine.medical_specialty, Pyridones, Population, [SDV.CAN]Life Sciences [q-bio]/Cancer, Pyrimidinones, 030204 cardiovascular system & hematology, Regression tree, 03 medical and health sciences, BRAF V600-mutation, 0302 clinical medicine, [SDV.CAN] Life Sciences [q-bio]/Cancer, Trametinib, Internal medicine, Antineoplastic Combined Chemotherapy Protocols, Oximes, medicine, Humans, Prospective Studies, Stage (cooking), Prospective cohort study, education, neoplasms, Melanoma, Aged, Neoplasm Staging, education.field_of_study, Proportional hazards model, business.industry, Dabrafenib, Imidazoles, Middle Aged, medicine.disease, 3. Good health, 030220 oncology & carcinogenesis, Mutation, Disease Progression, Female, business, Brain metastasis, medicine.drug
وصف الملف: application/pdf
الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7270e6beefeb71081cde6deee2aa0af2Test
https://hal.science/hal-03401780Test -
4
المؤلفون: Mohammed M. Milhem, Peter Mohr, Paul Nathan, Piotr Rutkowski, Anthony D'Amelio, Peter Hersey, Felix Kiecker, Jochen Utikal, Lev V. Demidov, Caroline Robert, Reinhard Dummer, Claus Garbe, Dirk Schadendorf, Jessica C. Hassel, Bijoyesh Mookerjee, James Larkin, Keith T. Flaherty
المساهمون: Department of Dermatology (CHU Besançon), Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC), N.N. Blokhin Russian Cancer Research Center, Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology (MCMCC), German Cancer Research Center - Deutsches Krebsforschungszentrum [Heidelberg] (DKFZ), Charité - UniversitätsMedizin = Charité - University Hospital [Berlin], Novartis Pharmaceutical Corporation, University of Zurich, Robert, Caroline
المصدر: European Journal of Cancer
European Journal of Cancer, Elsevier, 2019, 109, pp.61-69. ⟨10.1016/j.ejca.2018.12.015⟩مصطلحات موضوعية: 0301 basic medicine, Oncology, Male, Cancer Research, Skin Neoplasms, Time Factors, medicine.medical_treatment, [SDV]Life Sciences [q-bio], Medizin, Phases of clinical research, Targeted therapy, 0302 clinical medicine, Antineoplastic Combined Chemotherapy Protocols, 1306 Cancer Research, Melanoma, Trametinib, Aged, 80 and over, Brain Neoplasms, MEK inhibitor, Hazard ratio, 10177 Dermatology Clinic, Middle Aged, Prognosis, 3. Good health, Dacarbazine, Survival Rate, 030220 oncology & carcinogenesis, 2730 Oncology, Female, medicine.drug, Adult, Proto-Oncogene Proteins B-raf, medicine.medical_specialty, Paclitaxel, Pyridones, 610 Medicine & health, Pyrimidinones, 03 medical and health sciences, Young Adult, Internal medicine, medicine, Humans, Adverse effect, Aged, Chemotherapy, business.industry, 030104 developmental biology, Mutation, business, Follow-Up Studies
الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::28197cc98bbc5b4b985accfda8ddbdbdTest
https://pubmed.ncbi.nlm.nih.gov/30690294Test -
5
المؤلفون: John M. Kirkwood, James Larkin, Mario Mandalà, Richard F. Kefford, Tomas Haas, Vanna Chiarion-Sileni, Caroline Robert, Kohinoor Dasgupta, Axel Hauschild, Mario Santinami, Mark Shilkrut, Caroline Dutriaux, Eduard Gasal, Dirk Schadendorf, Georgina V. Long, Jacob Schachter, Andrew Haydon, Laurent Mortier, Ruth Plummer, Victoria Atkinson, Marta Nyakas, Thierry Lesimple, Reinhard Dummer
المساهمون: University of Zurich, Long, Georgina V
المصدر: Journal of Clinical Oncology
J Clin Oncolمصطلحات موضوعية: Male, 0301 basic medicine, Oncology, Cancer Research, Internationality, Skin Neoplasms, Time Factors, Medizin, 0302 clinical medicine, Antineoplastic Combined Chemotherapy Protocols, Oximes, Clinical endpoint, 1306 Cancer Research, Stage (cooking), Melanoma, Trametinib, Hazard ratio, Age Factors, Imidazoles, 10177 Dermatology Clinic, Middle Aged, Treatment Outcome, 030220 oncology & carcinogenesis, Female, 2730 Oncology, Rapid Communication, medicine.drug, Adult, Proto-Oncogene Proteins B-raf, medicine.medical_specialty, Pyridones, 610 Medicine & health, Pyrimidinones, Placebo, Disease-Free Survival, Drug Administration Schedule, 03 medical and health sciences, Sex Factors, Adjuvants, Immunologic, Double-Blind Method, Internal medicine, Correspondence, medicine, Humans, Dose-Response Relationship, Drug, business.industry, Cancer, Dabrafenib, medicine.disease, Clinical trial, 030104 developmental biology, business, Follow-Up Studies
وصف الملف: 767_Hauschild_A._et_al._Longer_follow-up_confirms_relapse-free_survival_benefit_with_adjuvant_dabrafenib_plus_trametinib_in_patients_JCO_2018.pdf - application/pdf
الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::00393631f41ac7c8491c0de2c7f007a8Test
https://doi.org/10.5167/uzh-158265Test -
6
المؤلفون: Christian U. Blank, Adil Daud, Rene Gonzalez, Kim Margolin, Scot Ebbinghaus, Ziwen Wei, Dirk Schadendorf, Antoni Ribas, Anna C. Pavlick, Lee D. Cranmer, Caroline Robert, April K.S. Salama, Jacob Schachter, Omid Hamid, Reinhard Dummer, Nageatte Ibrahim, F. Stephen Hodi, Igor Puzanov, Tara C. Gangadhar, Paolo A. Ascierto
المساهمون: University of Zurich, Hamid, Omid
مصطلحات موضوعية: 0301 basic medicine, Oncology, Male, Cancer Research, Skin Neoplasms, Time Factors, medicine.medical_treatment, Medizin, Phases of clinical research, Pembrolizumab, Kaplan-Meier Estimate, 0302 clinical medicine, Antineoplastic Agents, Immunological, 1306 Cancer Research, Melanoma, Aged, 80 and over, education.field_of_study, Cross-Over Studies, Drug Substitution, Hazard ratio, 10177 Dermatology Clinic, Middle Aged, MAP Kinase Kinase Kinases, Treatment Outcome, 030220 oncology & carcinogenesis, Disease Progression, 2730 Oncology, Female, medicine.drug, Adult, Proto-Oncogene Proteins B-raf, medicine.medical_specialty, Adolescent, Population, Ipilimumab, 610 Medicine & health, Antibodies, Monoclonal, Humanized, Disease-Free Survival, 03 medical and health sciences, Young Adult, Internal medicine, medicine, Humans, education, Protein Kinase Inhibitors, Aged, Chemotherapy, business.industry, medicine.disease, Confidence interval, Surgery, 030104 developmental biology, Drug Resistance, Neoplasm, Mutation, business
وصف الملف: 721_Hamid_O._et_al._Final_analysis_of_randomised_trial_comparing_pembrolizumab_versus_Eur_J_Cancer_2017.pdf - application/pdf
الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ab24a3779538f584d0432f320113cbb5Test
https://www.ncbi.nlm.nih.gov/pubmed/28961465Test -
7
المؤلفون: Céleste Lebbé, Anna Maria Di Giacomo, Helen Gogas, Georgina V. Long, Paolo A. Ascierto, Catalin Mihalcioiu, Francesco Cognetti, Ewa Kalinka-Warzocha, Kerry J. Savage, Cornelia Mauch, Ana Arance, Jasmine I. Rizzo, Lars Ny, Caroline Dutriaux, Piotr Rutkowski, Caroline Robert, Micaela Hernberg, Victoria Atkinson, Vanna Chiarion-Sileni, Benjamin Brady, Inge Marie Svane, Dirk Schadendorf, Jessica C. Hassel, Julie Charles, Laurent Mortier, Catriona M. McNeil, Abdel Saci, Joel Jiang
المصدر: JAMA Oncol
مصطلحات موضوعية: advanced melanoma, Adult, Male, Proto-Oncogene Proteins B-raf, Cancer Research, medicine.medical_specialty, Skin Neoplasms, Time Factors, Adolescent, Dacarbazine, Medizin, Phases of clinical research, Ipilimumab, Pembrolizumab, Placebo, BRAF, Young Adult, 03 medical and health sciences, Antineoplastic Agents, Immunological, 0302 clinical medicine, Double-Blind Method, Internal medicine, medicine, Humans, 030212 general & internal medicine, Nivolumab, wild-type, Antineoplastic Agents, Alkylating, Melanoma, Aged, Aged, 80 and over, business.industry, Hazard ratio, Correction, Middle Aged, medicine.disease, Treatment Outcome, Oncology, 030220 oncology & carcinogenesis, Disease Progression, Female, business, medicine.drug
الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a3c9b0d0b1e4e0e7e07096a725b4e567Test
https://doi.org/10.1001/jamaoncol.2018.4514Test -
8
المؤلفون: Stéphan Vagner, Alexander M.M. Eggermont, Lise Boussemart, Yungan Tao, Laurence Vilcot, Pierre Blanchard, Caroline Robert, Brigitte Dréno, Barouyr Baroudjian, Frédéric Dhermain, Christine Mateus, Eric Deutsch, Emilie Routier
المصدر: European journal of dermatology : EJD. 24(2)
مصطلحات موضوعية: Adult, Male, Proto-Oncogene Proteins B-raf, Radiosensitizer, Pathology, medicine.medical_specialty, Radiation-Sensitizing Agents, Indoles, Skin Neoplasms, medicine.medical_treatment, Dermatology, Remission induction, medicine, Combined Modality Therapy, Humans, Vemurafenib, Melanoma, Aged, 80 and over, Sulfonamides, business.industry, Remission Induction, Antitumor response, medicine.disease, Clinical trial, Radiation therapy, Cancer research, business, medicine.drug
الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::59d40e250153d141af1fea8d646604c0Test
https://pubmed.ncbi.nlm.nih.gov/24721778Test -
9
المؤلفون: Levi A. Garraway, Antje Sucker, Emanuele Palescandolo, Piotr Dziunycz, Damien Kee, Nyam Kamsu-Kom, Patrick A. Oberholzer, Günther F.L. Hofbauer, Grant A. McArthur, Clinton J. Chalk, Caroline Robert, Adriano Piris, Robert T. Jones, Kristin G. Ardlie, Dirk Schadendorf, Christine Roden, Laura E. MacConaill
المساهمون: University of Zurich, Garraway, L A
المصدر: Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 30(3)
مصطلحات موضوعية: Sorafenib, Adult, Male, Niacinamide, Proto-Oncogene Proteins B-raf, Cancer Research, Indoles, Skin Neoplasms, Genotype, Pyridines, Medizin, 610 Medicine & health, medicine.disease_cause, Mass Spectrometry, CDKN2A, Original Reports, Carcinoma, medicine, Humans, 1306 Cancer Research, HRAS, Vemurafenib, Protein Kinase Inhibitors, Aged, Aged, 80 and over, Mitogen-Activated Protein Kinase Kinases, Mutation, Sulfonamides, business.industry, Phenylurea Compounds, Benzenesulfonates, 10177 Dermatology Clinic, Middle Aged, medicine.disease, Gene Expression Regulation, Neoplastic, Oncology, Cancer research, Carcinoma, Squamous Cell, 2730 Oncology, Female, KRAS, business, medicine.drug
وصف الملف: RAS_Mutations_Are_Associated_With_the_Development_of_Cutaneous_Squamous_Cell_Tumors_in_Patients_Treated_With_RAF_Inhibitors_JCO_2011.pdf - application/pdf
الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c3567cff10b5be5b331260c345ce8a46Test
https://pubmed.ncbi.nlm.nih.gov/22067405Test -
10
المؤلفون: Sabine Druillennec, Alain Spatz, Vladimir Lazar, Philippe Dessen, Joost van den Oord, Caroline Robert, Brigitte Bressac-de Paillerets, Caroline Kannengiesser, Stefan Michiels, Alain Sarasin, Fabienne Lesueur, V. Winnepenninckx, Alain Eychène
المصدر: Molecular oncology. 1(4)
مصطلحات موضوعية: Neuroblastoma RAS viral oncogene homolog, Adult, Male, Proto-Oncogene Proteins B-raf, Cancer Research, Skin Neoplasms, Adolescent, Ultraviolet Rays, DNA Mutational Analysis, Mutation, Missense, Biology, medicine.disease_cause, Young Adult, Cell Movement, Gene expression, Genetics, medicine, Humans, Child, neoplasms, Melanoma, Aged, Regulation of gene expression, Aged, 80 and over, Mutation, Melanosomes, Gene Expression Profiling, Immunity, Infant, General Medicine, Middle Aged, medicine.disease, Microphthalmia-associated transcription factor, Molecular biology, digestive system diseases, Gene expression profiling, Gene Expression Regulation, Neoplastic, Genes, ras, Oncology, Child, Preschool, Cutaneous melanoma, Papers, Cancer research, Molecular Medicine, Female, DNA Probes
الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6aa656a369a59863ffb03c4699bc7235Test
https://pubmed.ncbi.nlm.nih.gov/19383316Test